Product
Eloctate
Aliases
rFVIIIFc
3 clinical trials
4 indications
Indication
Hemophilia AIndication
Coagulation factor VIIIIndication
Hemophilia Without InhibitorIndication
Hemophilia A with inhibitorClinical trial
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement TherapiesStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia AStatus: Terminated, Estimated PCD: 2022-04-06
Clinical trial
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia AStatus: Terminated, Estimated PCD: 2022-06-27